224 related articles for article (PubMed ID: 30552659)
1. Anatomy of Risk Evaluation and Mitigation Strategies (REMS).
Loeser KK; McKoy JM; Schumock GT
Cancer Treat Res; 2019; 171():93-105. PubMed ID: 30552659
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
[TBL] [Abstract][Full Text] [Related]
3. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
Toyserkani GA; Huynh L; Morrato EH
Front Public Health; 2020; 8():43. PubMed ID: 32158741
[No Abstract] [Full Text] [Related]
4. Assessment of risk evaluation and mitigation strategies in oncology: summary of the oncology risk evaluation and mitigation strategies workshop.
Frame JN; Jacobson JO; Vogel WH; Griffith N; Wariabharaj D; Garg R; Zon R; Stephens CL; Bialecki AM; Bruinooge SS; Allen SL
J Oncol Pract; 2013 Mar; 9(2):e24-39. PubMed ID: 23814522
[TBL] [Abstract][Full Text] [Related]
5. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).
Huynh L; Toyserkani GA; Morrato EH
BMC Health Serv Res; 2021 Aug; 21(1):779. PubMed ID: 34362367
[TBL] [Abstract][Full Text] [Related]
6. Examination of risk evaluation and mitigation strategies and drug safety in the US.
Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
[TBL] [Abstract][Full Text] [Related]
7. Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019.
Guadamuz JS; Qato DM; Alexander GC
JAMA; 2020 Jul; 324(3):299-301. PubMed ID: 32692379
[No Abstract] [Full Text] [Related]
8. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
Wu J; Juhaeri J
Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
[TBL] [Abstract][Full Text] [Related]
9. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
Shane R
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
[TBL] [Abstract][Full Text] [Related]
10. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the approved Risk Evaluation and Mitigation Strategy programs for New Drug Applications and Biologics Licensing Applications.
Johnson NA; Priefer R
Regul Toxicol Pharmacol; 2019 Feb; 101():53-56. PubMed ID: 30473489
[TBL] [Abstract][Full Text] [Related]
12. A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation.
Gabardi S; Tichy EM
Prog Transplant; 2013 Mar; 23(1):58-62; quiz 63. PubMed ID: 23448822
[TBL] [Abstract][Full Text] [Related]
13. FDA Adds Online REMS Table.
Aschenbrenner DS
Am J Nurs; 2017 Nov; 117(11):21. PubMed ID: 29076851
[No Abstract] [Full Text] [Related]
14. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.
Johnson PE; Dahlman G; Eng K; Garg R; Gottlieb S; Hoffman JM; Howell P; Jahanzeb M; Johnson S; Mackler E; Rubino M; Sarokhan B; Marc Stewart F; Tyler T; Vose JM; Weinstein S; Li EC; Demartino J;
J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S7-S27. PubMed ID: 20947724
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
[TBL] [Abstract][Full Text] [Related]
16. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
Leiderman DB
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
[TBL] [Abstract][Full Text] [Related]
17. Understanding risk evaluation and mitigation strategies in organ transplantation.
Gabardi S
Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
[TBL] [Abstract][Full Text] [Related]
18. FDA urged to reduce REMS program burdens.
Traynor K
Am J Health Syst Pharm; 2015 Nov; 72(22):1916-21. PubMed ID: 26541942
[No Abstract] [Full Text] [Related]
19. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
20. Managing the Risks of Medicines: An Examination of FDA's Application of Criteria for Requiring a REMS.
Seligman PJ; Anguiano RH; Felix T; Stabi K
Ther Innov Regul Sci; 2019 Jul; 53(4):542-548. PubMed ID: 30226799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
